Are GLP-1 Drugs the Future of Alcohol Addiction Treatment?

By Vijay Kumar MalesuReviewed by Lily Ramsey, LLM

How GLP-1 Drugs Work?
Scientific Evidence
Comparison to Existing Treatments: Effectiveness, Safety, And Accessibility
Challenges and Future Prospects
Conclusion

Addiction is a chronic relapsing condition with high morbidity and mortality. Despite existing psychosocial and pharmacological interventions, available medications are limited and often ineffective for many patients.

Image Credit: KK Stock/Shutterstock.com

Consequently, researchers are investigating new pharmacotherapies, including those that target the glucagon-like peptide-1 (GLP-1) system. Initially studied for diabetes management and obesity, GLP-1 receptor agonists (GLP-1RAs) have garnered interest for their potential in addressing substance use disorders.

Preclinical findings show that these medications can reduce drug use and craving by modulating reward pathways, stress responses, and cognitive functions. Although clinical research is in its early stages, emerging data, anecdotal reports, and pharmacoepidemiologic findings suggest these agents may be effective for alcohol, opioid, stimulant, and tobacco use disorders. However, important questions remain about their precise mechanisms of action, potential adverse effects, and which patient subgroups are most likely to benefit.¹

This article explores the emerging role of GLP-1RAs, originally developed for diabetes and obesity, in treating alcohol addiction. It analyzes the latest scientific findings, potential mechanisms of action, and how these drugs compare to existing treatment options.⁴

How Does Semaglutide Work to Lose Weight?

How GLP-1 Drugs Work?

GLP-1RAs have revolutionized the treatment of metabolic disorders, particularly type 2 diabetes and obesity. These drugs function by mimicking the natural hormone GLP-1, which is released by intestinal L cells in response to food intake.

Their primary role in metabolic regulation involves stimulating insulin secretion from pancreatic beta cells while inhibiting glucagon release. This dual effect helps maintain blood glucose levels and improves overall glycemic control. Additionally, GLP-1RAs slow gastric emptying, enhancing the feeling of fullness and reducing overall caloric intake, making them effective for weight management.^1,2

Beyond their metabolic effects, recent research has explored the role of GLP-1RAs in addiction regulation. The presence of GLP-1 receptors in the central nervous system, particularly in the ventral tegmental area (VTA) and nucleus accumbens (NAc), suggests their involvement in reward processing and motivation. These brain regions are critical in the development of substance use disorders (SUDs), where addictive substances hijack natural reward pathways, leading to compulsive behaviors.^1,2

Preclinical studies indicate that GLP-1RAs can modulate dopamine signaling, reducing drug-seeking behaviors and substance intake. Research in animal models has shown promising results, with reductions in alcohol, nicotine, and opioid consumption. Human clinical trials, though limited, have demonstrated a potential decrease in substance use among patients treated with GLP-1RAs, particularly for alcohol and tobacco use disorders.^1,2

While these findings are promising, further studies are necessary to establish the efficacy and safety of GLP-1RAs in addiction treatment. If confirmed, these drugs could offer a novel pharmacological approach to addressing both metabolic and behavioral disorders, bridging the gap between metabolic health and neuropsychiatric conditions.

Scientific Evidence

Several studies have explored the potential of GLP-1 RAs in treating alcohol use disorder (AUD). While initially developed for diabetes and obesity management, these drugs have been investigated for their impact on alcohol consumption due to their effects on the brain’s reward system.

While some studies found no effect on GLP-1 levels post-alcohol intake, others noted reductions in heavy drinkers. Genetic variations in GLP-1R are linked to AUD risk and brain activity differences. Trials suggest mixed results, with reductions in heavy drinking in obese AUD patients. Pharmacoepidemiologic studies support lower alcohol-related events with GLP-1R agonists.³

A systematic review analyzed six key studies involving 88,190 participants, with 38,740 (43.9%) receiving GLP-1 RAs. Among these, two randomized controlled trials (RCTs) examined the direct impact of GLP-1 RAs on alcohol intake. The first RCT, focusing on exenatide, reported no significant reduction in alcohol consumption over 24 weeks. However, subgroup analysis suggested that individuals with obesity (Body mass index (BMI) >30 kg/m²) showed a decline in alcohol use and reduced cue reactivity in brain reward centers on Functional magnetic resonance imaging (fMRI). Another RCT investigating dulaglutide found a 29% greater likelihood of reduced alcohol consumption compared to placebo. Observational studies supported these findings, indicating fewer alcohol-related healthcare events among GLP-1 RA users compared to non-users or those on alternative treatments.⁴

Who Should Take Weight Loss Injections, and Who Shouldn’t?

Comparison to Existing Treatments: Effectiveness, Safety, And Accessibility

Evaluating the effectiveness, safety, and accessibility of new treatment modalities in comparison to traditional therapies is essential in assessing their potential impact. Conventional treatments for SUDs and AUD primarily rely on pharmacotherapy, behavioral interventions, and support systems. However, relapse rates remain high, and many currently approved medications exhibit limitations in efficacy and patient adherence.⁵

GLP-1RAs have emerged as potential alternatives for treating addiction-related behaviors. Unlike traditional medications such as disulfiram, naltrexone, and buprenorphine, which primarily target neurotransmitter pathways directly associated with addiction, GLP-1RAs modulate reward mechanisms indirectly through metabolic and neuroendocrine pathways.

Preclinical studies have demonstrated their ability to reduce drug-seeking behavior and substance intake, with promising results in alcohol, nicotine, and stimulant use disorders. Their mechanism involves the modulation of dopamine signaling in the mesolimbic system, suggesting a broader therapeutic impact across multiple forms of addiction.⁵

From a safety perspective, GLP-1RAs have an established profile due to their widespread use in diabetes and obesity management. Unlike opioid-based treatments, they do not carry risks of dependency. Initial concerns regarding pancreatitis and gastrointestinal side effects have been mitigated through extensive clinical trials, which indicate a generally favorable risk-benefit ratio. However, long-term studies specific to addiction treatment are required to confirm their safety in this new application.⁵

Accessibility remains a key consideration. While existing treatments for AUD and SUDs are often limited by regulatory restrictions and stigma, GLP-1RAs may benefit from their established approval for metabolic disorders. Their availability in oral and injectable formulations also enhances patient adherence. However, cost and insurance coverage could pose barriers, particularly in lower-income populations.⁵

Challenges and Future Prospects

Despite promising findings, GLP-1RAs face limitations in addiction treatment. Their efficacy varies across different substances, with inconsistent results observed in chronic alcohol use models. Potential side effects, including nausea and concerns regarding long-term safety, remain under investigation. Additionally, most preclinical studies predominantly focus on male subjects, leaving gender-specific effects unclear.^3,5

Ongoing research aims to explore the precise mechanisms through which GLP-1RAs modulate addiction-related behaviors. Preclinical data suggest interactions with dopamine pathways, but human trials remain limited. Some studies report a reduction in alcohol and nicotine intake, whereas results for opioids and stimulant use disorders are less conclusive. Large-scale clinical trials are necessary to determine long-term effectiveness, optimal dosing strategies, and potential individual variations in response.^3,5

Regulatory considerations play a crucial role in the adoption of GLP-1RAs for addiction treatment. The United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved GLP-1RAs for the treatment of type 2 diabetes mellitus and obesity but not for substance use disorders.

Although early trials indicate potential benefits, widespread adoption requires rigorous evaluation of safety and efficacy. Given the high prevalence of addiction and the limited availability of effective treatments for cocaine and stimulant use disorders, GLP-1-based therapies offer hope. However, regulatory agencies must assess potential benefits against associated risks, ensuring robust clinical evidence before approval. Future research should focus on patient-specific responses, genetic factors, and long-term outcomes to refine treatment approaches.^3,5

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Conclusion

GLP-1RAs, originally developed for diabetes and obesity, are emerging as potential treatments for SUDs. Preclinical studies suggest these drugs modulate reward pathways, reduce cravings, and influence stress responses. Clinical research, though limited, shows promising results, particularly in alcohol and nicotine use disorders. Observational studies indicate fewer alcohol-related healthcare events among GLP-1RA users.

Compared to traditional addiction treatments, GLP-1RAs offer a novel mechanism by targeting metabolic and neuroendocrine pathways rather than direct neurotransmitter modulation. Their established safety profile in metabolic disorders makes them attractive alternatives, though concerns remain about long-term effects, cost, and accessibility.

Large-scale trials are needed to refine dosing strategies and confirm benefits. While not yet approved for addiction treatment, GLP-1RAs hold significant potential in addressing addiction’s complex neurobiological underpinnings.

References

1. Bruns, V. N., Tressler, E. H., Vendruscolo, L. F., Leggio, L., & Farokhnia, M. (2024). IUPHAR review-Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target. Pharmacological Research, 107312.
2. Martinelli, S., Mazzotta, A., Longaroni, M., & Petrucciani, N. (2024). Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: a systematic review of randomized trials. Drug and Alcohol Dependence, 112424.
3. Bruns, V. N., Tressler, E. H., Vendruscolo, L. F., Leggio, L., & Farokhnia, M. (2024). IUPHAR review-Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target. Pharmacological Research, 107312. https://doi.org/10.1016/j.phrs.2024.107312
4. Subhani, M., Dhanda, A., King, J. A., Warren, F. C., Creanor, S., Davies, M. J., ... & Aithal, G. P. (2024). Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review. EClinicalMedicine.
5. Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022). The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders. British Journal of Pharmacology, 179(4), 625-641.

Further Reading

• All Addiction Content
• Tremors Following Alcohol Dependency
• Video Game Addiction Symptoms, Diagnosis and Treatment
• Sun Addiction: Evolutionary Survival Advantage?
• What is Heroin Addiction?